Current Perspectives of Anticoagulation in Patients With COVID-19

Sayın Meslektaşlarımız,

Journal of Cardiovascular Pharmacology dergisinde yayınlanan Current Perspectives of Anticoagulation in Patients With COVID-19 isimli makaleyi paylaşmak isteriz.

Makaleye ulaşmak için lütfen tıklayınız.

Saygılarımızla
Türkiye EKMUD

Abstract: Thromboembolism and myocardial injury is common in patients with COVID-19. Low-molecular-weight heparin appears to be associated with a good prognosis in patients with COVID-19 and has the ability to reduce coagulation and inflammation markers. Hospitalized patients with COVID-19 should be placed on throm- boprophylaxis with the option of full therapeutic anticoagulation or tissue plasminogen activator in high-risk or mechanically ventilated patients. Thromboprophylaxis should also be considered at hospital discharge for high-risk patients. Clinical judgment should be used to evaluate the bleeding and safety risk of anticoagulation in patients with COVID-19 without confirmed data.